ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Shire To Acquire Ferrokin Biosciences

by Rick Mullin
March 19, 2012 | APPEARED IN VOLUME 90, ISSUE 12

To bolster its hematology business, Shire, the Dublin-based biopharmaceutical company, has agreed to acquire FerroKin BioSciences for an up-front payment of $100 million. Shire is interested in San Carlos, Calif.-based FerroKin’s iron chelator, FBS0701. “There remains a significant unmet need for a once-a-day, oral iron chelator in a convenient dosage for the treatment of transfusional iron overload with a better safety profile than currently available treatments,” says Ross Murdoch, senior vice president of hematology at Shire. The companies plan to file new drug applications for FBS0701 to treat myelodysplastic syndrome and hemoglobinopathies. FerroKin stands to earn clinical and regulatory milestone payments of $225 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment